Cargando…

Anakoinosis: Communicative Reprogramming of Tumor Systems - for Rescuing from Chemorefractory Neoplasia

Disruptive technologies, such as communicative reprogramming (anakoinosis) with cellular therapies in situ for treating refractory metastatic cancer allow patient care to accelerate along a totally new trajectory and highlight what may well become the next sea change in the care of patients with man...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hart, Christina, Vogelhuber, Martin, Wolff, Daniel, Klobuch, Sebastian, Ghibelli, Lina, Foell, Jürgen, Corbacioglu, Selim, Rehe, Klaus, Haegeman, Guy, Thomas, Simone, Herr, Wolfgang, Reichle, Albrecht
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Netherlands 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4542828/ https://www.ncbi.nlm.nih.gov/pubmed/26259724 http://dx.doi.org/10.1007/s12307-015-0170-1

Ejemplares similares

Anakoinosis: Correcting Aberrant Homeostasis of Cancer Tissue—Going Beyond Apoptosis Induction
por: Heudobler, Daniel, et al.
Publicado: (2019)

Clinical Efficacy of a Novel Therapeutic Principle, Anakoinosis
por: Heudobler, Daniel, et al.
Publicado: (2018)

A Computational Model of Tumor Growth and Anakoinosis
por: Pantziarka, Pan, et al.
Publicado: (2019)

Editorial: Anakoinosis: An Innovative Anticancer Therapy Targeting the Aberrant Cancer Tissue Homeostasis
por: Heudobler, Daniel, et al.
Publicado: (2021)

Editorial: Anakoinosis for promoting tumor tissue editing: Novel therapeutic opportunities for establishing clinically relevant tumor control by targeting tumor plasticity
por: Heudobler, Daniel, et al.
Publicado: (2022)

Editorial: Tumor Systems Biology: How to Therapeutically Redirect Dysregulated Homeostasis in Tumor Systems (i.e., Anakoinosis)
por: Reichle, Albrecht, et al.
Publicado: (2020)

Biomodulatory Treatment With Azacitidine, All-trans Retinoic Acid and Pioglitazone Induces Differentiation of Primary AML Blasts Into Neutrophil Like Cells Capable of ROS Production and Phagocytosis
por: Klobuch, Sebastian, et al.
Publicado: (2018)

Peroxisome Proliferator-Activated Receptors (PPAR)γ Agonists as Master Modulators of Tumor Tissue
por: Heudobler, Daniel, et al.
Publicado: (2018)

Metronomics: Intrinsic Anakoinosis Modulator?
por: Nicolas, André, et al.
Publicado: (2018)

Biomodulatory Treatment Regimen, MEPED, Rescues Relapsed and Refractory Classic Hodgkin’s Disease
por: Lüke, Florian, et al.
Publicado: (2021)

Communicative reprogramming non-curative hepatocellular carcinoma with low-dose metronomic chemotherapy, COX-2 inhibitor and PPAR-gamma agonist: a phase II trial
por: Walter, I., et al.
Publicado: (2017)

Low-dose trofosfamide plus rituximab is an effective and safe treatment for diffuse large B-cell lymphoma of the elderly: a single center experience
por: Schelker, Roland Christian, et al.
Publicado: (2018)

Cutaneous Leukemic Infiltrates Successfully Treated With Biomodulatory Therapy in a Rare Case of Therapy-Related High Risk MDS/AML
por: Heudobler, Daniel, et al.
Publicado: (2018)

Lowering Etoposide Doses Shifts Cell Demise From Caspase-Dependent to Differentiation and Caspase-3-Independent Apoptosis via DNA Damage Response, Inducing AML Culture Extinction
por: Bruni, Emanuele, et al.
Publicado: (2018)

Unusual Late Relapse of ALK-Positive Anaplastic Large Cell Lymphoma Successfully Cleared Using the ALK-Inhibitor Crizotinib: Case Report
por: Harrer, Dennis Christoph, et al.
Publicado: (2020)

Biomodulatory metronomic therapy in stage IV melanoma is well‐tolerated and may induce prolonged progression‐free survival, a phase I trial
por: Hart, C., et al.
Publicado: (2015)

A Randomized Phase II Trial Comparing the Efficacy and Safety of Pioglitazone, Clarithromycin and Metronomic Low-Dose Chemotherapy with Single-Agent Nivolumab Therapy in Patients with Advanced Non-small Cell Lung Cancer Treated in Second or Further Line (ModuLung)
por: Heudobler, Daniel, et al.
Publicado: (2021)

All-Oral Low-Dose Chemotherapy TEPIP is Effective and Well-Tolerated in Relapsed/Refractory Patients With Aggressive B-Cell Lymphoma
por: Fante, Matthias A., et al.
Publicado: (2022)

Drug Repurposing by Tumor Tissue Editing
por: Lüke, Florian, et al.
Publicado: (2022)

Androgen Deprivation Freezes Hormone-Sensitive Prostate Cancer Cells in a Reversible, Genetically Unstable Quasi-Apoptotic State, Bursting into Full Apoptosis upon Poly(ADP-ribose) Polymerase Inhibition
por: Pelliccia, Andrea, et al.
Publicado: (2023)

Role of delayed salvage bevacizumab at symptomatic progression of chemorefractory glioblastoma
por: Cuncannon, Moire, et al.
Publicado: (2019)

Comparing the Secretomes of Chemorefractory and Chemoresistant Ovarian Cancer Cell Populations
por: Lee, Amy H., et al.
Publicado: (2022)

Apoptosis as Driver of Therapy-Induced Cancer Repopulation and Acquired Cell-Resistance (CRAC): A Simple In Vitro Model of Phoenix Rising in Prostate Cancer
por: Corsi, Francesca, et al.
Publicado: (2022)

All-oral low-dose chemotherapy TEPIP is effective and well-tolerated in patients with peripheral T-cell lymphoma
por: Fante, Matthias A., et al.
Publicado: (2023)

Advantages of the Combinatorial Molecular Targeted Therapy of Head and Neck Cancer—A Step before Anakoinosis-Based Personalized Treatment
por: Kleszcz, Robert
Publicado: (2023)

Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers
por: Hancock, Bradley A., et al.
Publicado: (2019)

Readministration of Cancer Drugs in a Patient with Chemorefractory Metastatic Colorectal Cancer
por: Kawagoe, Tetsuro, et al.
Publicado: (2020)

Chemorefractory Gastric Cancer: The Evolving Terrain of Third-Line Therapy and Beyond
por: Alsina, Maria, et al.
Publicado: (2022)

Successful Treatment of Early Relapsed High-Risk AML After Allogeneic Hematopoietic Stem Cell Transplantation With Biomodulatory Therapy
por: Kattner, Anna-Sophia, et al.
Publicado: (2020)

Efficacy and safety of the third-generation chloroethylnitrosourea fotemustine for the treatment of chemorefractory T-cell lymphomas
por: Corazzelli, Gaetano, et al.
Publicado: (2011)

Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer
por: Geva, Ravit, et al.
Publicado: (2013)

Gemcitabine plus capecitabine (Gem–Cape) biweekly in chemorefractory metastatic colorectal cancer
por: Jiménez-Fonseca, P., et al.
Publicado: (2014)

The role of large volume re-irradiation with Bevacizumab in chemorefractory high grade glioma
por: Chan, Joseph, et al.
Publicado: (2020)

Pericardial Effusion during Proton Therapy in a Patient with Chemorefractory Hodgkin Lymphoma
por: Way, Ashley, et al.
Publicado: (2021)

Erratum to: Gemcitabine plus capecitabine (Gem–Cape) biweekly in chemorefractory metastatic colorectal cancer
por: Jiménez-Fonseca, P., et al.
Publicado: (2014)

Genomic mutations and histopathologic biomarkers in Y(90) radioembolization for chemorefractory colorectal liver metastases
por: Dendy, Meaghan S., et al.
Publicado: (2018)

Anti-PD-1 therapy plus chemotherapy versus anti-PD-1 therapy alone in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia: a multicenter, retrospective study
por: Wang, Xiaoyu, et al.
Publicado: (2023)

Haploidentical γδ T Cells Induce Complete Remission in Chemorefractory B-cell Non-Hodgkin Lymphoma
por: Bold, Anna, et al.
Publicado: (2023)

RETRO-TAS, a Retrospective Observational Study of Trifluridine/Tipiracil in Chemorefractory Metastatic Colorectal Cancer
por: Koumarianou, Anna, et al.
Publicado: (2023)

Metabolic Reprogramming of Castration-Resistant Prostate Cancer Cells as a Response to Chemotherapy
por: Petrella, Greta, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_57phi7mq297pkvsdlrnpres65l